📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. The Quality Overall Summary — the high-level synopsis of the chemistry, manufacturing, and controls (Module 3).
Why it exists. Module 3 quality data are voluminous; the QOS distills the drug substance, drug product, specifications, and stability into the summary a quality reviewer reads first, pointing to the detail in Module 3.
How it is produced here. No real manufacturing was done, so the chemistry, manufacturing, and controls detail is deep-knowledge mock — realistic, standard-conformant content standing in for real CMC data.
Format & governing standard. ICH M4Q(R1) §2.3 · Q6A/Q6B · Q1A(R2)/Q5C · Q2(R2) · Q3A/Q3B · Q8–Q11
| Field | Value |
|---|---|
| Document ID | M23 |
| Version | 2.0 (submission-grade) |
| Compound | GLPI-103 (GLP-1/APJ dual agonist peptide) |
| Sponsor | Virtual Biopharma Inc. |
| Standard | ICH M4Q(R1) §2.3 · Q6A/Q6B · Q1A(R2)/Q5C · Q2(R2) · Q3A/Q3B · Q8–Q11 |
| Confidentiality | Confidential — portfolio use |
[MOCK — deep-knowledge assumption]Summarizes Module 3 (M3, M3-S, M3-P, M3-QTPP, M3-CS, M3-AMV, M3-PV, M3-STAB, M3-AR); illustrative values. No CMC data are generated by this project.
No comments yet. Be the first to say something!
| Version | Date | Author | Summary of Change |
|---|---|---|---|
| 1.0 | 2026-06-29 | CMC / Quality | Initial version |
| 2.0 | 2026-07-05 | CMC / Quality | Submission-grade — expanded S/P/A/R subsections, control strategy, process/analytical validation, and stability; aligned to the detailed Module 3 leaves |
GLPI-103 is a synthetic peptide dual agonist of the GLP-1 and APJ receptors, presented as two drug products: a sterile solution for once-weekly intravenous use (P-IV) and a once-daily oral immediate-release tablet (P-Oral) containing a permeation enhancer. The quality package is built on a Quality Target Product Profile and Critical Quality Attributes (M3-QTPP) and a control strategy (M3-CS) developed under ICH Q8–Q11 quality-by-design principles.
GLPI-103 drug substance is manufactured by solid-phase peptide synthesis (SPPS) with fatty-acid acylation and non-natural residues, followed by RP-HPLC purification and lyophilization (M3.2.S.2).
Pharmaceutical development (P.2) links formulation and process parameters to the CQAs and to clinical performance (biopharmaceutics, M2.7.1). Both processes are validated across the lifecycle (M3-PV; ICH Q8/Q11); container-closure systems are qualified; ICH stability supports the proposed shelf lives (M3-STAB).
Facilities and equipment, and adventitious-agents safety, are addressed; adventitious-agent risk is low for a fully synthetic peptide (no biological starting materials). The novel excipient (permeation enhancer) is supported by appropriate qualification (M3-AR §3.2.A).
Region-specific quality information (executed batch records, method-validation packages, comparability, and process-validation scheme) is provided per FDA, EMA, and MFDS expectations (M3-AR §3.2.R).
The Quality (CMC) package supports a well-characterized, consistently manufactured drug substance and two drug products with justified specifications, validated analytical and manufacturing processes, qualified container-closure systems, and adequate stability, consistent with the clinical formulations used across the development program (PROT-301; M2.7.1). The control strategy assures that each batch meets its CQAs, providing a robust quality basis for the marketing application.